NASDAQ:ALLO

Allogene Therapeutics Stock Predictions

etoro logo Buy ALLO
*Your capital is at risk
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

ALLO Prediction Chart

ALLO Predictions History

Latest community submissions for ALLO.
Predictor Target Session Target Price Result Direction Accuracy Score
Aug 13, 2025 $1.06 +2.53% $1.03 X 97.47% 0
Aug 13, 2025 $1.06 +2.91% $1.03 X 97.09% 0
Jun 11, 2025 $1.41 -3.37% $1.45 V 97.30% 1
Jun 11, 2025 $1.43 -2.10% $1.45 V 98.57% 2
Jun 11, 2025 $1.56 +6.85% $1.45 X 92.41% 0
May 21, 2025 $1.20 +3.45% $1.11 X 91.89% 0
May 13, 2025 $1.25 +6.84% $1.13 X 89.38% 0
May 6, 2025 $1.72 +6.17% $1.28 X 65.63% 0
Mar 17, 2025 $2.00 +3.26% $1.85 X 91.72% 0
Mar 17, 2025 Bullish $1.85 X 0
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for ALLO with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT ALLOGENE THERAPEUTICS INC.
Allogene Therapeutics
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE